Investor Presentaiton slide image

Investor Presentaiton

Oncology Hematology Cell Therapy Immunology Cardiovascular Opdivo (anti-PD1) Metastatic Trials Indication Phase/Study # of Patients Design • 1L MIUC Phase III CheckMate -901 - N = 1,290 PD-L1+ & cis-ineligible: Opdivo 1 mg/kg + Yervoy 3 mg/kg Q3W up to 4 cycles followed by Opdivo 480 mg Q4W vs SOC chemotherapy Cis-eligible: Opdivo 360 mg in combination with chemotherapy Q3W vs SOC chemotherapy Primary: PFS, OS in cis-eligible patients Endpoints OS in PD-L1+ (>=1%) & cis-ineligible 2L RCC SC Phase III CheckMate -67T - • Opdivo +rHuPH20 SC Opdivo IV N = 454 Primary: Cavgd28 (Opdivo serum concentration) ⚫ Cminss Status CT Identifier Positive topline results in cis-eligible in July 2023 Data presented at ESMO 2023 as a Late Breaker in the Presidential Symposium • Cis-eligible data published in NEJM October 2023 • Projected data readout 2024 in cis-ineligible Did not meet primary OS endpoint in PD-L1+ NCT03036098 ll Bristol Myers Squibb™ | Q3 2023 Results • Key secondary: ORR • Positive topline results in October 2023 NCT04810078 Not for Product Promotional Use 35
View entire presentation